Dismay but little surprise as NICE rejects Alzheimer's drugs
Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Gilead's twice-yearly PrEP drug is cleared by FDA
Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Amid sector disruption, biotech must focus on 'fundamentals'...
The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Biogen bids to extend use of Skyclarys to younger patients
Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
App to support people with depression launches in GB
A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
EVERSANA expands commercialisation portfolio with OS Therapi...
EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic partnerships to support the US commercialisation of innovative therapies from O
The Pharmaceutical Marketing Society and the Chartered Insti...
The PM Society is delighted to announce a new partnership with the CIM to build capability and excellence in marketing in the pharmaceutical industry.
15th World Clinical Biomarkers & Companion Diagnostics Summi...
The biomarkers and diagnostics field continues to boom, driven by advancements in genomic profiling, omics, and AI technologies.
5th iPSC Drug Development Summit
Advance iPSC therapies from bench to bedside with 30+ industry experts at this year’s summit.
Axtria Ignite 2025: Leading in an Agentic Era
Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This